CFMG & Wellpath in California — a documentary investigation · Article 028 of 100 · Series 3 — Physician executives, ownership and succession

The Missing Stock-Transfer Agreement

Published

20 September 2026, 6:00 PM PT

Content last changed

25 September 2026

Public-evidence cutoff

25 September 2026

Sources checked

25 September 2026

Record through

25 September 2026

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

The Missing Stock-Transfer Agreement is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

The governing question is narrow: Why one unavailable CFMG document may matter more than hundreds of branding examples. The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

The contract record shows a recurring county-side misdescription#

Multiple county/public sources use formulations such as:

• “CFMG dba Wellpath”

• “CFMG/Wellpath”

• “CFMG, now Wellpath”

• “Wellpath, formerly CFMG”

• “CFMG dba Wellpath Management, Inc.”

• “CFMG commonly known as Wellpath”

These formulations should not be collapsed into one legal proposition.

They may represent:

• brand usage;

• County shorthand;

• vendor-system nomenclature;

• mistaken corporate succession assumptions;

• or actual contractual DBA language.

The federal bankruptcy record proves why this matters: CFMG remained a distinct professional corporation.

Thus county nomenclature is best treated as:

evidence of how the healthcare operation presented itself and was understood by the governmental client.

That is highly relevant to operational identity.

It is not enough to establish corporate genealogy.

The bankruptcy record also contains the strongest structural investigative evidence yet#

The same record identifies facts that require deeper review:

• Wellpath itself calls the model a friendly professional corporation structure.

• The PCs generated more than $674 million in annual revenue for the benefit of the Debtors .

• The Debtors remitted approximately $720 million in PC operating costs.

• The Debtors collected certain PC receivables.

• The Debtors handled payroll, benefits, taxes, and deductions for PC employees.

• The Debtors and certain physician owners were parties to Stock Transfer Agreements.

• Those agreements restricted transfer of physician shares.

• The stated purpose included continuation of the Debtors’ administrative services.

• The Debtors said they had authority under those agreements to ensure PCs remained licensed and qualified.

• The Debtors argued that Professional Corporation Contracts and organizational documents were executory contracts involving estate interests.

• The Debtors said they “maintain an interest” in the PCs.

• The motion uses the facially inconsistent phrase “ownership interests in the Professional Corporations.”

• The Debtors considered continued PC relationships essential to their own reorganization.

• New PC contracts during bankruptcy required five-business-day notice to DIP lenders and the Ad Hoc Group.

• CFMG litigation was sufficiently economically connected to Wellpath through insurance and indemnity that the Debtors repeatedly sought stay protection.

• No public CFMG-specific board record has yet been found showing an independent decision to continue with Wellpath during or after the restructuring.

None of these facts alone establishes unlawful control.

Together, they make the stock-transfer and board records indispensable.

The december 2018 county record is one of the earliest public examples of CFMG/Wellpath identity blending#

Only months after CFMG began operating the Fresno contract, a Fresno County behavioral-health advisory record stated that a name change had recently occurred from CFMG to Wellpath, while also stating that the organization would continue to operate under CFMG and the Fresno contract would remain with CFMG .

The same County record referred to the Fresno agreement as the largest Wellpath contract and described Wellpath operational personnel, including a regional operations director.

Primary County minutes:

https://www.fresnocountyca.gov/files/sharedassets/county/v/1/vision-files/files/35776-dec-2018-minutes.pdf

This is exceptionally useful because it documents the identity ambiguity essentially at the moment it arose.

The County’s language can be summarized:

Public operating name changed to Wellpath; legal contract remained CFMG.

The “name change” wording should not be interpreted as an actual corporate conversion.

Later federal cases and bankruptcy records establish that CFMG did not simply change its legal name to Wellpath.

But the County record explains why employees, patients, counsel, and courts later used the names interchangeably.

The 2019 physician onboarding record shows Wellpath as the employee-facing identity#

The clearest public evidence of how a Fresno physician experienced the arrangement is the litigation record itself — the J.S. docket, the Overfield discovery orders, and the county contract files — each of which places the professional corporation and the management organization in defined roles without resolving who held final authority in any particular clinical decision.

In September 2019, a Wellpath recruiter sent benefit information describing the position as employment with:

Wellpath at Fresno County Jail

and explained that, because CCS and CMGC had merged, legacy groups would come together under a single benefits plan in January 2020.

In October 2019, the same Wellpath recruitment channel described California benefits as applicable to legacy CMGC sites and supplied malpractice information.

These communications are significant because they were sent at the start of the physician relationship, not reconstructed years later in litigation.

They show that employee-facing onboarding used the Wellpath enterprise identity.

But they should not be overread.

A recruiter can use enterprise branding even when the technical employer is a professional corporation.

The correct conclusion is:

From the physician’s perspective, Fresno onboarding was operationally presented through Wellpath, while the formal employer relationship later asserted by the companies was CFMG.

This is one of the earliest concrete Fresno examples of the formal/operational split.

II. Structural and Historical Context#

Records that would resolve the question#

• Actual Rule 7.1 / interested-entity PDFs from Beckner , Sand , Avila , Strieter , and post-bankruptcy CFMG cases.

• Every Overfield exhibit concerning Chapman termination.

• Chapman’s continued deposition once filed.

• Any renewed Hole deposition.

• Complete Smith same-entity stipulation and financial discovery record.

• Complete D.M. discovery correspondence supporting the same-functions representation.

• Complete Andrew Ho bankruptcy/arbitration references; public filings only.

• Napa Agreement 190201B and every amendment.

• County-by-county executed agreements and RFP proposals.

• CFMG/Wellpath quality-review policies implicated by Kartchner .

• Bankruptcy insurance/indemnity schedules naming CFMG.

• The 2012 MSA exhibits and every later amendment.

• All stock-transfer restriction / succession instruments referenced by the 2019 assignment.

• CFMG bylaws and shareholder/officer history.

• Physician employment templates pre-2018 vs post-2018.

• Wellpath enterprise clinical-policy approval matrices for California.

Shareholder-succession event table to build once the agreement is found#

For every historical owner transfer:

The likely historical periods needing reconstruction are:

• founder era;

• 2012–2013 H.I.G. transaction;

• Fithian/Herr transition;

• 2018 CCS–CMGC combination;

• Herr/Bazzel transition;

• 2024 bankruptcy;

• 2025 lender emergence;

• 2026 Local Government–California restructuring.

The chronology should remain blank where ownership is unproven rather than inferring ownership from officer titles.

III. The Control and Governance Analysis#

Documents with the highest evidentiary value#

the investigation should prioritize obtaining and authenticating:

• complete December 31, 2012 MSA;

• all amendments and restatements;

• 2019 assignment documents;

• stock-transfer restriction agreements;

• shareholder succession / replacement agreements;

• CFMG articles, bylaws, shareholder agreements, and board minutes;

• complete list of CFMG shareholders/directors/officers by year;

• “Company Designee” appointments;

• Wellpath/CFMG delegation-of-authority matrices;

• physician hiring and termination workflows;

• physician compensation approval matrices;

• HRIS and payroll audit trails;

• EHR ownership and administrator records;

• clinical policy approval metadata;

• county RFP responses describing management hierarchy;

• malpractice/GL coverage and indemnity instruments;

• outside-counsel retention/claims administration protocols;

• quality assurance and mortality-review governance documents;

• management-fee and intercompany accounting records;

• post-bankruptcy amendments or succession instruments.

Subpages#

• Corporate timeline: 1983–2026

• The 2012 Management Services Agreement

• H.I.G. Capital and the 2013 investment

• The 2018 CCS–CMGC transaction and creation of Wellpath

• The 2019 management assignment

• CFMG physician ownership and governance

• California county contracts

• Physician employment and HR control

• Physician compensation and payroll

• Medical records and EHR control

• Clinical policy and operational control

• Litigation defense and claims administration

• Pre-bankruptcy litigation positions

• Bankruptcy and the rediscovery of CFMG

• Post-bankruptcy California litigation

• Smith v. Santa Cruz County

• D.M. v. County of Merced

• Hernandez v. County of Monterey

• Overfield v. Wellpath / CFMG

• Fresno case study: Miles, Henderson, and J.S.

• California CPOM law and 2026 enforcement

• Evidence matrix

• Case index

• Primary-document library

• Open questions / records not yet public

Every page should include a visible Evidence Level badge and a What this does not prove section.

The hallman "no ownership overlap" statement is important but not dispositive#

In November 2024, Wellpath board co-chair Kip Hallman told the Santa Barbara Independent that:

• CFMG was a wholly separate entity;

• it was owned primarily by group physicians;

• CFMG contracted with Wellpath for management services;

• the entities had no ownership overlap.

This is among the clearest contemporaneous public descriptions of formal ownership.

Santa Barbara County later described CFMG similarly as a separate physician-owned entity operating in California with a business relationship with Wellpath.

These statements materially undermine allegations that Wellpath or H.I.G. directly held CFMG physician stock.

But the statements do not answer:

• stock-transfer restrictions;

• succession control;

• veto rights;

• contractual replacement rights;

• collateral;

• management dependence;

• practical ability to replace the MSO.

"No ownership overlap" and "no control rights" are different propositions.

Level 5 — Control consequence established#

Exercise of the right demonstrably determined ownership, governance, clinical independence, or the practice's ability to replace its MSO.

Current coding:

Stock-transfer restrictions: Level 1.

Their existence is expressly referenced; content unknown.

MSA assignment asymmetry: Level 2–3.

The right exists and was actually used in 2019.

18% fee: Level 2.

Original formula established; current percentage unknown.

Bank-account disbursement authority: Level 2.

Contractual authority established; exercise not yet mapped.

Security interest: Level 2.

Grant established; UCC filing/exercise unknown.

Deficit funding: Level 1–2.

MSA reference established; underlying agreement missing.

Termination acceleration: Level 2.

Contractual consequence established; exercise unknown.

Governance participation: Level 2.

Contractual right established; actual meeting practice unknown.

The january 1, 2019 assignment put Wellpath llc directly into the manager position#

The next essential instrument is the January 1, 2019 Assignment. It identifies CFMG as the “Company,” Wellpath LLC as the “Manager,” and Wellpath Management, Inc., formerly Correctional Medical Group Companies, Inc. / California Forensic Management Group, Inc., as the “Outgoing Manager.”

The assignment does not dissolve CFMG or replace it with Wellpath. Instead, it changes the party occupying the management side of the existing PC–MSO relationship. The outgoing manager irrevocably assigns the Management Services Agreement to Wellpath LLC together with related or incidental instruments, including relevant stock-transfer restriction agreements.

Primary source:

https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf

This creates the critical prepetition baseline:

CFMG professional corporation ↔ Wellpath LLC manager

not:

CFMG ↔ Wellpath Holdings.

That distinction becomes central in bankruptcy because the ultimate parent changed dramatically while Wellpath LLC itself remained the identified contracting manager .

Why the stock-transfer document is different from the MSA#

The Management Services Agreement tells us who administers the business.

The stock-transfer agreement may tell us who ultimately controls the owner of the medical corporation.

That distinction is fundamental.

A lawful MSO can perform extensive administrative services for an independently controlled medical corporation.

Examples may include:

• payroll;

• accounting;

• IT;

• HR administration;

• insurance;

• procurement;

• billing;

• compliance support;

• scheduling support;

• records infrastructure;

• contracting support.

The physician corporation can remain substantively independent if the physician owners retain real authority over professional matters and meaningful governance power over the corporation.

A stock-transfer instrument becomes more consequential because it can affect the person who holds the legal voting stock.

If the MSO merely prevents an unqualified person from inheriting professional-corporation stock and provides an orderly mechanism for transfer to another independently selected qualified physician, the agreement may function as a legitimate compliance and continuity device.

If, by contrast, the MSO can decide who owns the PC, replace the owner at will, or cause the owner to lose stock for challenging the MSO, then the agreement can give the MSO leverage over every decision formally assigned to the physician owner.

The legal inquiry therefore changes from:

“Who performs management services?”

to:

“Who can remove the person who is supposed to control the professional corporation?”

The CFMG-specific evidence begins with the 2019 assignment#

The January 1, 2019 Assignment of Management Services Agreement is direct CFMG evidence.

The instrument provides that the outgoing manager transferred to Wellpath LLC:

• the MSA;

• the manager’s rights, responsibilities, duties, and obligations;

• and related or incidental instruments, expressly including relevant stock-transfer restriction agreements .

Primary source:

https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf

This is not a generic statement about friendly PCs.

It is a signed instrument specifically involving:

• CFMG;

• Wellpath LLC;

• and the outgoing management-company lineage.

Therefore the existence of at least one CFMG-related stock-transfer restriction instrument is strongly supported.

What the assignment does not reveal is its content.

That distinction is essential.

The bankruptcy motion explains how Wellpath’s stock-transfer agreements generally functioned#

The November 12, 2024 Professional Corporation Motion supplies the enterprise-level explanation.

Wellpath described its PC model as a “friendly professional corporation” structure in which professional entities were owned by licensed physicians while Wellpath supplied management and administrative services.

The filing says the debtors and certain physician owners were parties to Stock Transfer Agreements that:

• restricted transfer of professional-corporation stock;

• facilitated orderly ownership transitions;

• supported compliance with professional-entity laws;

• addressed transfer events such as death and disability;

• promoted continuity of care;

• and promoted continued administrative services by the Wellpath debtors.

The filing further states that the debtors possessed authority under those agreements to help ensure that the PCs remained properly licensed and qualified.

Primary source:

In re Wellpath Holdings, Inc., No. 24-90533, Docket No. 15 (Bankr. S.D. Tex. Nov. 12, 2024).

https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1124325&docketNumber=15&projectCode=WPT&source=DM

These are major facts.

But the pleading refers generally to “certain PC Physicians.”

It does not say that every professional corporation had exactly the same transfer provisions.

Thus:

CFMG-specific assignment + enterprise-level description = strong reason to investigate, but not permission to invent the missing CFMG terms.

The 2026 art center amicus brief supplies the most precise current control theory#

The California Attorney General’s March 30, 2026 amicus brief in Art Center Holdings significantly sharpens the legal framework.

The Attorney General’s position is that a nonprofessional corporation can violate California’s corporate-practice prohibition not only by exercising medical control, but also by retaining the right to exercise control .

The analysis focuses on contractual arrangements under which:

• the MSO can replace the physician-owner with another physician of its choosing;

• the physician cannot sell the PC without MSO approval;

• termination of the owner-side arrangement can cause the physician’s stock to be transferred;

• while the physician owner cannot freely remove the MSO without risking ownership.

The Attorney General argues that such rights effectively give the MSO ultimate control because the physician owner knows that disobedience can cost the physician ownership of the practice.

Primary source:

California Attorney General, Brief of Amicus Curiae in Support of Neither Party, Art Center Holdings, Inc. v. WCE CA Art, LLC , No. B338625 (Cal. Ct. App., 2d App. Dist., Div. 3, Mar. 30, 2026), on appeal from Los Angeles County Superior Court No. 24SMCV01185.

https://oag.ca.gov/system/files/attachments/press-docs/Brief%20of%20the%20California%20Attorney%20General%20as%20Amicus%20Curiae%20in%20Support%20of%20Neither%20Party.pdf

This is not yet a holding that every stock-transfer agreement is illegal.

The analysis itself recognizes that not every MSO–PC relationship contains an impermissible degree of control.

The importance is that this analysis right is now a central California enforcement question.

H. What are the stock-transfer restrictions?#

The 2019 assignment references related stock-transfer restriction agreements.

The exact documents remain missing from the authenticated primary corpus.

That gap has become more important after the Attorney General's 2026 focus on physician-owner replacement and succession rights.

The defense must be able to show that Wellpath cannot:

• select the CFMG owner;

• compel transfer to its chosen successor;

• veto physician ownership;

• or effectively prevent CFMG from replacing the MSO.

If the restrictions are ordinary professional-corporation compliance devices, production should substantially strengthen the defense.

A right to control ownership would be especially consequential#

The current California enforcement lens matters here.

The Attorney General's pending Art Center position is that contractual rights allowing an unlicensed MSO to replace a physician owner can themselves compromise the independence required by California law.

Carbon Health similarly involved allegations that contractual ownership/succession mechanisms made medical groups effectively captive.

The CFMG record contains a reference to stock-transfer restriction agreements but not the complete instruments.

The control side can therefore argue:

Until those agreements are produced, the investigation's largest structural-control question remains unanswered.

This is not proof that CFMG has a Carbon-style continuity arrangement.

It is the reason the documents are Tier One.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.

Provisional legal / factual conclusion#

The best-supported reconstruction at present is:

Wellpath LLC became CFMG’s manager by the January 1, 2019 assignment. The January 2019 CFMG MSA remained operative during Wellpath’s Chapter 11. The confirmed Plan used a blanket assumption rule under which unrejected executory contracts re-vested in the applicable contracting Post-Restructuring Debtor on the May 9, 2025 Effective Date. The final rejection schedule in the public record does not identify CFMG, although it does expressly reject another professional-corporation relationship. The restructuring changed ultimate ownership of the Wellpath enterprise but did not, on the evidence currently located, require a new assignment of the CFMG MSA away from Wellpath LLC. A 2026 Sonoma County agreement independently confirms that Wellpath LLC continued to function as CFMG’s MSO after emergence.

The remaining uncertainty concerns exact cure/schedule treatment, related stock-transfer agreements, private amendments, and CFMG physician-board action.

That is a much narrower uncertainty than existed at the start of the bankruptcy inquiry.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.

The CFMG management agreement was assigned to Wellpath LLC in 2019#

A January 1, 2019 assignment, later filed in Wellpath’s Chapter 11 case and made publicly available, transferred CFMG’s management-services agreement from its prior management entity to Wellpath LLC. The document says the assignment was undertaken for the efficiency of administering management functions. It also states that the assignment included related or incidental instruments, including “relevant stock transfer restriction agreements.” Source: 2019 MSA Assignment

The assignment establishes the existence or reference to those related agreements. It does not disclose their operative terms. The ownership-and-succession consequences of those documents therefore remain an open public-record question.

Layer eleven: the 2019 assignment and stock-transfer restrictions#

The January 2019 assignment is one of the most consequential public documents.

It transferred the management agreement to Wellpath LLC.

It also says the assignment included related or incidental instruments, including relevant stock transfer restriction agreements .

That phrase should be handled with care.

It establishes a documentary trail.

It does not establish what rights the stock-transfer instruments contained.

The public investigation should therefore resist the temptation to fill the gap with facts from unrelated “friendly PC” cases.

Instead, the proper question is simple:

What do the CFMG-specific stock-transfer and succession documents actually say?

Until those documents are located, the answer remains open.

The stock-control question has moved to the top tier#

The 2019 assignment references related stock-transfer restriction agreements.

California’s 2026 enforcement posture makes those documents potentially decisive.

The principal questions are:

• Who selects a successor CFMG shareholder?

• Can Wellpath/MSO nominate, approve, veto, remove, or cause replacement of a physician shareholder?

• Is there a transfer-restriction agreement, succession agreement, proxy, option, nominee arrangement, succession list, or irrevocable power?

• What happens to shares when a physician owner dies, resigns, loses licensure, or leaves employment?

• Who controls the purchase price?

• Who funds the purchase?

• Does the MSO hold security interests or contractual rights tied to the shares?

• Can CFMG terminate the MSA without losing critical systems, staff, brand, financing, or contracts?

• Can a CFMG shareholder remove Wellpath as manager in practice?

The difference between economic dependence and legal control must be preserved.

A PC can be economically dependent on an MSO without the MSO legally owning it. But if the MSO controls who may own or govern the PC, California regulators may view the arrangement very differently.

The central missing documents are now the stock-transfer restrictions#

The January 1, 2019 Assignment of Management Services Agreement is a critical instrument.

It identifies:

• CFMG as the "Company";

• Wellpath LLC as the new "Manager";

• Wellpath Management, Inc., formerly Correctional Medical Group Companies, Inc. and California Forensic Management Group, Inc., as the "Outgoing Manager."

The operative language does more than assign the MSA.

It states that the outgoing manager:

irrevocably assigns the Management Services Agreement to Wellpath LLC along with any related or incidental instruments including but not limited to relevant stock transfer restriction agreements .

That sentence is one of the most consequential facts uncovered in the entire project.

The stock-transfer restrictions were important enough to be expressly carried into the Wellpath structure along with the MSA.

Yet the actual agreements have not been located in the public corpus in the public record.

That creates a Tier One evidentiary gap.

The bankruptcy did not reorganize CFMG stock through the debtor plan#

Because CFMG was a nondebtor professional corporation, the Wellpath Chapter 11 did not simply convert CFMG stock into lender equity in the manner that debtor-company equity was restructured.

That distinction matters.

Wellpath itself announced in May 2025 that ownership of the reorganized Wellpath enterprise transitioned to a group of current and former lenders.

Public SEC filings by Prospect Capital show that its Wellpath debt was converted into debt and equity positions in New WPCC Parent, LLC . Prospect subsequently reported holdings including Series A Preferred Interests and Class A Common Interests in New WPCC Parent.

Those records illuminate the new ownership of the management enterprise.

They do not establish that New WPCC Parent owns CFMG's physician stock.

The more precise question is:

What happened to the MSA, stock-transfer restrictions, management rights, security interests, and succession mechanisms when the Wellpath management enterprise changed ownership?

That is the post-bankruptcy continuity issue.

Shareholder#

The shareholder owns the professional corporation's stock.

Because CFMG is a California professional medical corporation, stock ownership is subject to California professional-corporation restrictions.

A shareholder's identity must be established through:

• stock ledger;

• stock certificate;

• shareholder agreement;

• transfer record;

• corporate minutes;

• authenticated corporate filing or admission.

A title alone is insufficient.

The current shareholder question remains unanswered#

This is perhaps the most important conclusion of the prior analysis.

The January and November 2025 California Statements of Information tell us:

• officers;

• directors;

• addresses.

They do not tell us:

• shareholders;

• share percentages;

• stock certificates;

• beneficial ownership;

• succession rights.

Wellpath has publicly described CFMG as physician-owned.

Kip Hallman publicly described it as owned primarily by a group of physicians and said there was no ownership overlap with Wellpath.

Those are meaningful corporate statements.

But the actual ownership schedule has not yet been obtained.

Accordingly, the record should not publish:

• "Bazzel owns CFMG";

• "Bazzel, Medrano and Kennedy are the shareholders";

• "Taranath is a CFMG shareholder";

• "Wellpath owns CFMG";

• "H.I.G. owns CFMG stock."

None of those propositions is currently established by sufficiently reliable primary evidence.

Where the missing stock documents may exist#

Potential repositories include:

• CFMG corporate minute book;

• corporate counsel records;

• Wellpath legal department;

• management-company contract repository;

• bankruptcy diligence/data room;

• H.I.G. transaction files;

• lender diligence files;

• UCC/collateral documentation;

• former officer records;

• county due-diligence submissions if ownership certifications were required;

• malpractice/insurance underwriting files;

• California regulatory filings;

• tax records.

The 2019 assignment proves that at least some stock-transfer restriction instruments existed.

That makes their absence from the public record a retrieval problem, not a reason to assume their contents.

Why bankruptcy is a true governance stress test#

The ordinary PC–MSO relationship asks whether a physician-owned professional corporation is genuinely independent while buying administrative support from a management company.

Chapter 11 adds a much harder question:

What does the physician corporation do when its exclusive manager becomes insolvent, enters Chapter 11, changes owners, and reorganizes the operating structure?

For an independent principal, that event should at least create the possibility of:

• evaluating the manager’s solvency;

• assessing contract breach/default rights;

• evaluating alternative managers;

• deciding whether to continue the MSA;

• reassessing management fees;

• obtaining independent legal advice;

• examining data/records continuity;

• considering malpractice and insurance continuity;

• evaluating effects on physician employment;

• approving any required assignment or post-emergence transition;

• and documenting the physician board’s judgment.

A decision to remain with Wellpath could be entirely rational.

The test is not whether CFMG changed managers.

The test is whether CFMG exercised an identifiable independent corporate choice .

To date, this investigation has not identified publicly filed CFMG board minutes, shareholder resolutions, independent-counsel memoranda, or other CFMG-specific governance records documenting such a decision.

That absence must be interpreted cautiously.

CFMG was a nondebtor professional corporation. Its internal board materials were not necessarily required to be filed in the Wellpath bankruptcy.

Thus the correct conclusion is not:

“CFMG’s board did nothing.”

The correct conclusion is:

The public bankruptcy record reviewed to date contains extensive evidence of what Wellpath’s Debtors sought to preserve in the PC relationships, but comparatively little public evidence of what CFMG’s physician board independently decided about continuing that relationship.

That asymmetry itself defines the next documentary inquiry.

WHAT WOULD CONSTITUTE STRONG CONTRARY EVIDENCE?#

The following would be substantially more consequential:

• Wellpath or lender documents selecting CFMG’s shareholder successor without meaningful physician choice;

• stock-transfer instruments requiring continuation of Wellpath as manager;

• CFMG board action occurring only after Wellpath implementation;

• automatic continuation of the MSA despite a formal assignment/ownership change requiring consent;

• documents showing the Wellpath side could replace the CFMG owner/director;

• lender covenants directly controlling CFMG governance;

• CFMG unable to terminate the manager without losing its stock, contracts, accounts, records, or operating assets.

No such CFMG-specific document has yet been established publicly in this investigation.

That is precisely why the missing stock and governance instruments matter.

High-priority bankruptcy documents for the next pass#

• Docket No. 194 and its complete potential-assumed-contract schedule.

• All supplements to Docket No. 194.

• Docket Nos. 2039, 2189, 2498, and 2551 rejection schedules.

• Plan Supplement Docket Nos. 2321 and 2555.

• First Amended Plan Docket No. 2376-1 and technical modifications Docket No. 2552-1.

• Schedule of assumed executory contracts at emergence.

• Any specific entry for the CFMG MSA.

• Any CFMG cure amount.

• Any notice served directly on CFMG.

• Any CFMG objection, reservation, consent, or response.

• Any stock-transfer agreement listed as executory.

• Any CFMG organizational document listed as executory.

• Any post-effective-date assumption/assignment of the CFMG MSA.

• New WPCC Parent LLC agreement.

• lender governance/board-appointment rights.

• restructuring-transaction steps involving Wellpath LLC / Wellpath Management.

• documents concerning Wellpath CFMG, Inc. f/k/a CFMG Holdings Corp. to preserve entity distinctions.

• CFMG board minutes November 2024–June 2025.

• CFMG shareholder minutes during restructuring.

• CFMG independent-counsel engagement records.

• post-emergence CFMG MSA amendments.

• 2026 Local Government–California authority/delegation records.

The bankruptcy record sharpens the central cpom question#

The bankruptcy evidence does not prove that Wellpath practiced medicine through CFMG.

It does something more useful.

It reveals the architecture of dependence .

The Debtors themselves described:

• a friendly-PC structure;

• physician ownership;

• deep administrative control;

• major economic reliance on PC revenues;

• stock-transfer restrictions tied to management continuity;

• authority relating to PC licensing/qualification;

• insurance;

• payroll;

• collections;

• taxes;

• legal support;

• indemnification;

• lender notice over new PC contracts.

California law then asks a separate question:

Did those structural rights and dependencies remain on the lawful administrative side of the line, or did they give the nonprofessional management enterprise practical or contractual authority over decisions reserved to physicians?

That question still requires the CFMG-specific stock, board, and authority records.

Article v.f makes the missing stock agreements more, not less, important#

One might initially assume that confirmation rendered the stock-transfer issue irrelevant. The opposite is true.

If the MSA was broadly assumed together with related agreements and interests, then determining the exact scope of the CFMG-related instruments becomes even more important.

The 2019 Assignment expressly links the MSA, related/incidental instruments, and stock-transfer restriction agreements. The bankruptcy PC Motion separately describes stock-transfer agreements as part of the friendly-PC system and says they support continuity of Debtor administrative services. Article V.F then uses broad language about modifications, amendments, supplements, restatements, related agreements, options, rights, and interests.

The convergence of those documents means the CFMG-specific stock instrument should now be treated as a Plan-continuity document , not merely a historical ownership document.

The exact instrument could reveal whether ownership-succession control also crossed the May 9, 2025 restructuring boundary.

Current confidence assessment#

2019 Assignment made Wellpath LLC the manager: Very High.

January 2019 CFMG MSA remained operative in February 2025: Very High.

Final Plan used blanket assumption as default: Very High.

California Forensic Medical Group absent from final searchable rejection schedule: High, subject to indexing/name limitations.

No reviewed earlier rejection notice identifies CFMG: High, subject to the same caveat.

Another PC relationship was affirmatively rejected: Very High.

CFMG MSA was therefore deemed assumed on May 9, 2025: High-confidence documentary/legal inference.

Wellpath LLC remained applicable contracting post-restructuring manager: High.

A new public assignment to New WPCC Parent was required: Not supported.

New WPCC Parent acquired CFMG physician stock: Not established.

CFMG expressly consented to the assumption: Unknown.

CFMG board independently deliberated about continuing Wellpath: Unknown from public record.

CFMG stock-transfer restriction agreement survived through Article V.F: Plausible and important inference; not yet proven from the exact instrument.

Bankruptcy makes the control-instrument question more urgent#

the prior analysis indicates that the CFMG MSA most likely continued through Wellpath’s Chapter 11 under the Plan’s blanket assumption mechanism.

The 2019 assignment also placed stock-transfer restrictions in the Wellpath LLC relationship.

The confirmed Plan contains broad language treating assumed contracts as including related agreements and interests unless separately rejected.

This creates a plausible path by which stock-control rights could have continued after May 9, 2025.

But the precise bankruptcy treatment of the CFMG stock agreement remains unknown.

Questions:

• Was the stock agreement separately scheduled?

• Was it considered an executory contract?

• Was it considered an organizational document?

• Was it amended at emergence?

• Did lender ownership alter any rights?

• Did the physician shareholder sign a reaffirmation?

These questions should be treated as Plan implementation issues, not merely historical corporate questions.

Specific document request language#

A targeted request should seek:

All stock transfer agreements, stock transfer restriction agreements, shareholder succession agreements, continuity agreements, assignable options, stock powers, proxies, powers of attorney, nominee agreements, escrow agreements, buy-sell agreements, and related amendments concerning any shares of California Forensic Medical Group, Incorporated, including all agreements assigned or referenced in the January 1, 2019 Assignment of Management Services Agreement.

It should also request:

All documents identifying any person or entity with authority to nominate, approve, reject, remove, replace, or designate a CFMG shareholder, director, officer, Chief Executive Officer, or Company Designee.

That language is considerably more precise than requesting “ownership records” generically.

Records with the highest probative value#

• articles of incorporation;

• bylaws, all relevant versions;

• shareholder agreements;

• stock certificates and ledgers;

• stock-transfer restriction agreements;

• succession agreements;

• options;

• proxies;

• voting agreements;

• nominee agreements;

• custodial/escrow agreements;

• death/disability succession instruments;

• buy-sell agreements;

• board/shareholder resolutions approving ownership arrangements;

• 2012 MSA and all exhibits;

• assignment into Wellpath structure;

• every amendment/restatement/waiver;

• deficit-funding agreements;

• collateral/security agreements;

• UCC filings;

• deposit-account control agreements;

• MSA termination notices/rights analyses;

• documents addressing transition away from the manager.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 027 — Officer Is Not Owner: The Most Important Corporate-Governance Correction in the Record

• Article 029 — Did CFMG Own Wellpath LLC? The Federal 'Corporate Parent' Disclosure Anomaly

• Article 026 — Dheeraj Taranath and the Enterprise Clinical Layer

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: Why one unavailable CFMG document may matter more than hundreds of branding examples. A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are stock transfer, share ownership, succession rights, and missing primary evidence. The source spine identified in the current public record is: 2019 assignment reference; bankruptcy generic stock-transfer model; ownership/succession theory; missing ledger/certificates. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for The Missing Stock-Transfer Agreement should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. The governing question is narrow: Why one unavailable CFMG document may matter more than hundreds of branding examples. The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

How each source is used#

The following public authorities are tied to defined propositions in this article. They are not interchangeable: each is cited for the institutional purpose it can actually prove, and none is treated as a universal finding about ownership, employment, liability, or professional control.

• 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012. Used here as operative baseline for the allocation of management functions, physician-reserved responsibilities, and the manager/professional-corporation relationship.
• 2019 Assignment of Management Services Agreement, effective Jan. 1, 2019 — CFMG remained the Company while Wellpath LLC became the Manager. Used here as dated evidence of management succession without, by itself, eliminating CFMG's separate professional-corporation identity.
• California Corporations Code § 13401.5, Moscone-Knox Professional Corporation Act. Used here as the professional-corporation ownership and licensed-person framework relevant to shareholder, director, officer, and professional-employee questions.
• California Business and Professions Code § 2400. Used here as the statutory anchor for California's prohibition on the unlicensed corporate practice of medicine.
• California Attorney General, Apr. 1, 2026, amicus announcement defending California's corporate-practice-of-medicine prohibition in Art Center Holdings. Used here as a current California enforcement position emphasizing rights of control over professional functions, not merely formal labels.
• Wellpath public announcement concerning Grand Prairie Healthcare Services, P.C. and Wellpath LLC as management-services organization (Oct. 2021), together with Michigan transition records. Used here as the strongest comparator for testing whether a Wellpath-managed professional corporation could transition away from the enterprise and what an actual exit looked like.

The California enforcement record, 2021–2026#

This missing instrument is now the direct CFMG analogue to the Attorney General’s principal concern in Art Center — whether a management company’s contractual power to replace the physician owner amounts to effective ownership — and to the succession and option provisions described in the Carbon Health complaint. Art Center is an amicus position in a pending appeal, and Carbon a complaint with a court-approval-dependent settlement; neither is a finding about CFMG. But together they make this the highest-priority unresolved document in the investigation.

Relevant control indicators: Owner replacement / succession — highest-priority unresolved. See the California control-indicator matrix in California’s Corporate-Practice Enforcement Record, 2021–2026. Added 25 September 2026.

Sources and authorities#

1. 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012 — https://www.prisonlegalnews.org/news/publications/california-forensic-medical-group-incorporated-management-services-agreement/
2. 2019 Assignment of Management Services Agreement, effective Jan. 1, 2019 — CFMG remained the Company while Wellpath LLC became the Manager — https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf
3. California Corporations Code § 13401.5, Moscone-Knox Professional Corporation Act — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=CORP&sectionNum=13401.5.
4. California Business and Professions Code § 2400 — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=BPC&sectionNum=2400.
5. California Attorney General, Apr. 1, 2026, amicus announcement defending California's corporate-practice-of-medicine prohibition in Art Center Holdings — https://oag.ca.gov/news/press-releases/attorney-general-bonta-files-amicus-brief-defense-california%E2%80%99s-ban-corporate
6. Wellpath public announcement concerning Grand Prairie Healthcare Services, P.C. and Wellpath LLC as management-services organization (Oct. 2021), together with Michigan transition records

Citation rule: These sources support only the propositions identified in the article and source analysis. A party filing remains a party position unless adopted by a court; a corporate announcement remains a corporate representation; a contract proves allocated rights but not necessarily implementation; and a regulator's guidance or enforcement position is not an adjudication against CFMG unless a cited matter says so.